Blog Post Package: SBIR vs. R01

Write a Product Plan, Not an R01: SBIR vs. R01 for Researchers

If you've written an R01, you already know how NIH review works. That's a real advantage when you apply for an NIH SBIR or STTR grant. It's also the most common reason strong researchers lose.

The short answer to SBIR vs. R01: NIH scores both with the same five criteria: Significance, Investigator(s), Innovation, Approach, and Environment. The difference is what reviewers are judging. An R01 asks whether you'll answer an important scientific question. An SBIR asks whether this small business can turn the science into a product that reaches patients.

NIH's SBIR review system is built on the R01 system. That's exactly why applications that read like an R01 look familiar to reviewers and still fall short.

Same criteria, different questions

Researchers often assume that because the criteria match, the writing should too. The criteria are the same headings. The questions under them are not.

SBIR reviewers judge Phase II applications on Phase I results, scientific and technical merit, and commercial potential. They also use the Commercialization Plan, which can run up to 15 pages, when scoring Significance. And under Significance, they ask whether the project could lead to a marketable product, process, or service.

So "Significance" in an SBIR application isn't only "this disease matters." It's "this disease matters, current options fall short in a specific way, and this product closes that gap for a defined user."

Rewrite aims as milestones, not questions

This is the single biggest change researchers need to make. R01 aims explore. SBIR aims prove.

Here's how one of our clients framed a $4.3M Direct to Phase II award for a pediatric heart pump. Each aim was a build-and-test step toward a device children could go home with:

1.      Develop the driveline that connects the implanted pump to an external controller.

2.      Build the wearable controller, battery, and handheld patient monitor.

3.      Show performance and biocompatibility in a 30-day large-animal study.

4.      Prove durability in a 6-month accelerated benchtop test.

There's no open-ended question. Every aim names a component, a test, and a result reviewers can picture.

A smaller example works the same way. A $330K Phase I award for a nerve diagnostic used three aims: build a stimulation probe that fits existing pain-management needles, develop the algorithm that links stimulation to the muscle response, and measure repeatability in an animal model. The application then named the next step, the testing needed for FDA 510(k) clearance.

Quick rewrite test: for each aim, ask "If this works, what can the product do that it couldn't before?" If you can't answer in one sentence, the aim is still an R01 aim.

Define the market, even in Phase I

Many researchers treat commercialization as a Phase II problem. That's a mistake. Even in Phase I, reviewers weigh commercial potential under Significance.

You don't need a 15-page plan for Phase I. You do need clear answers to:

·        Who uses the product: surgeon, ICU nurse, patient, or lab?

·        What do they use today, and where does it fall short?

·        What evidence would make them switch?

·        What is the regulatory path, such as 510(k), De Novo, PMA, or IND?

·        Who could fund or partner on the next stage?

Our clients' wins show how specific this can be. One application pointed out that more than 30 million intubations happen in the U.S. each year, and that misplaced breathing tubes cost about $12B a year. That framing helped win a $467K Phase I award for a self-positioning breathing tube.

Build the team around the product, not the lab

In an R01, the Investigator criterion centers on the PI's publication record. In an SBIR, reviewers also want to see that the team can build and commercialize. That usually means adding:

·        An engineer or product-development lead

·        A regulatory consultant who knows your FDA pathway

·        A clinical advisor who represents the end user

·        Letters of support from potential users, partners, or manufacturers

Where the PI works matters too. For an SBIR, the PI's primary employment (more than 50%) should be with the small business, while an STTR PI can be employed by either the company or the partner research institution. For faculty who want to keep their appointment, that often makes STTR the better fit. Our guide, Can University Researchers Get NIH SBIR/STTR Funding?, walks through the choice.

Three R01 habits that cost SBIR points

1. Leading with mechanism. R01 reviewers want the biology. SBIR reviewers want the problem the product solves. Put the clinical gap first and the mechanism second.

2. Proposing "more data." "Generate additional preclinical data" isn't a milestone. Name the threshold, such as a power target, a sensitivity level, or a durability duration, and the decision it unlocks.

3. Treating Environment as the university. For SBIR, Environment includes the company. Show where the company's work happens, who leads it, and how the university fits in. That's especially important for STTR, where at least 40% of the work must happen at the small business and at least 30% at the research institution.

Phase I, Fast-Track, or Direct to Phase II?

Researchers with strong existing data often don't need to start at Phase I. Two of our clients' largest awards, $2.6M and $4.3M, were Direct to Phase II applications for implantable heart pumps. Both teams already had large-animal feasibility data, so they skipped Phase I and asked for funding to complete pre-clinical testing.

A simple rule of thumb:

·        Phase I: you need to prove the core concept works.

·        Fast-Track: you can define clear Phase I milestones and a credible Phase II plan now.

·        Direct to Phase II: you already have feasibility data equivalent to a completed Phase I

Read more in our Direct to Phase II step-by-step guide and our post on Phase I milestones.

Frequently asked questions

Is an SBIR easier to win than an R01?
Not necessarily easier, but different. SBIR applications compete in their own pool, reviewed by panels that include both academic and industry scientists. Researchers who adapt their writing to product milestones are often more competitive there than in R01 pools.

Can I submit the same project as an R01 and an SBIR?
The two have different applicants and goals. An R01 funds a research institution's science; an SBIR funds a company's product development. The projects should be clearly distinct, and NIH doesn't allow duplicate funding of the same work.

Do SBIR reviewers score commercialization?
Commercial potential is weighed under Significance. Phase II, Fast-Track, and Phase II renewal applications must also include a Commercialization Plan that reviewers use when scoring Significance.

Do I need a company before applying?
Yes. An eligible U.S. small business must apply and receive the award. A university can take part as a partner or subcontractor, and is required as a partner for STTR.

Are SBIR and STTR still funded?
Yes. Congress reauthorized both programs through September 30, 2031.

Get a reviewer's read on your aims

Blue Haven's lead grant writer serves on federal grant review panels. We help researchers rewrite academic aims into product milestones that SBIR reviewers fund, and with BHGC Pay Upon Award™, you pay only if you're funded.

Our clients have won $8.6M in NIH SBIR awards. See their success stories or start with our page for researchers.

Request a free aims review

Next
Next

NIH SBIR Phase I Milestones: How to Show Your Innovation Is Ready for the Next Step